Better treatment during early stages of chronic kidney disease (CKD) may slow progression to end-stage renal disease and decrease associated complications and medical costs. Achieving early treatment of CKD is challenging, however, because a large fraction of persons with CKD are unaware of having this disease. Screening for CKD is one important method for increasing awareness. We examined the cost-effectiveness of identifying persons for early-stage CKD screening (i.e., screening for moderate albuminuria) using published CKD risk scores.
We used the CKD Health Policy Model, a micro-simulation model, to simulate the cost-effectiveness of using CKD two published risk scores by Bang et al. and Kshirsagar et al. to identify persons in the US for CKD screening with testing for albuminuria. Alternative risk score thresholds were tested (0.20, 0.15, 0.10, 0.05, and 0.02) above which persons were assigned to receive screening at alternative intervals (1-, 2-, and 5-year) for follow-up screening if the first screening was negative. We examined incremental cost-effectiveness ratios (ICERs), incremental lifetime costs divided by incremental lifetime QALYs, relative to the next higher screening threshold to assess cost-effectiveness. Cost-effective scenarios were determined as those with ICERs less than $50,000 per QALY. Among the cost-effective scenarios, the optimal scenario was determined as the one that resulted in the highest lifetime QALYs.
ICERs ranged from $8,823 per QALY to $124,626 per QALY for the Bang et al. risk score and $6,342 per QALY to $405,861 per QALY for the Kshirsagar et al. risk score. The Bang et al. risk score with a threshold of 0.02 and 2-year follow-up screening was found to be optimal because it had an ICER less than $50,000 per QALY and resulted in the highest lifetime QALYs.
This study indicates that using these CKD risk scores may allow clinicians to cost-effectively identify a broader population for CKD screening with testing for albuminuria and potentially detect people with CKD at earlier stages of the disease than current approaches of screening only persons with diabetes or hypertension.
United States Renal Data System (USRDS). US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.
Smith D, Nichols G, Gullion C, Johnson E, Keith D. Predicting costs of care in chronic kidney disease: the role of comorbid conditions. Internet J Nephrol. 2007;4(1). doi: 10.5580/1d9e.
Ruggenenti P, Perna A, Mosconi L, Group G, et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63. CrossRef
Weinstein M, Siegel J, Gold M, Kamlet M, Russell L. Cost-effectiveness in heath and medicine. New York: Oxford University Press; 1996.
Meenan RT, Saha S, Chou R, Swarztrauber K, Krages KP, O’Keeffe-Rosetti MC, McDonagh M, Chan BK, Hornbrook MC, Helfand M. Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack. Med Decis Making. 2007;27(2):161–77. CrossRefPubMed
Physician Fee Schedule Search, 2007. http://www.cms.hhs.gov/pfslookup/02_PFSsearch.asp. Accessed 1 Oct 2010.
2007 Clinical Diagnostic Laboratory Fee Schedule—07CLAB. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html?redirect=/ClinicalLabFeeSched/02_clinlab.asp#TopOfPag. Accessed 12 Apr 2010.
2005 national estimates on hospital use for all patients. HCUP Nationwide Inpatient Sample (NIS). http://hcupnet.ahrq.gov/. Accessed 18 May 2010.
Drug Topics. Red Book. Oradell, NJ: Medical Economics Co; 2007.
2004 state estimates on emergency department use. HCUP State Inpatient Database (SID) and State Emergency Department Databases (SEDD). http://hcupnet.ahrq.gov/. Accessed 10 May 2010.
- The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
Benjamin O. Yarnoff
Thomas J. Hoerger
Siobhan K. Simpson
Nilka R. Burrows
Sundar S. Shrestha
Meda E. Pavkov
on behalf of the Centers for Disease Control and Prevention CKD Initiative
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II